The correct version of this piece can be read at https://www.dispatchtribunal.com/2017/09/24/adams-diversified-equity-fund-inc-acquires-177900-shares-of-johnson-johnson-jnj.html. The Capital Planning Advisors Llc holds 41,317 shares with $5.47 million value, down from 45,517 last quarter. Scotia Capital Inc who had been investing in Johnson & Johnson for a number of months, seems to be less bullish one the $351.69 billion market cap company. The company’s stock had a trading volume of 4,334,862 shares.
Johnson & Johnson (NYSE:JNJ) last posted its quarterly earnings results on Tuesday, July 18th. It has underperformed by 4.16% the S&P500.
James Investment Research Inc decreased Ceco Environmental Corp (NASDAQ:CECE) stake by 37,200 shares to 88,730 valued at $815,000 in 2017Q2. Fisher Asset Management LLC now owns 11,499,415 shares of the company’s stock valued at $1,521,258,000 after purchasing an additional 405,517 shares in the last quarter. The company reported $1.83 earnings per share for the quarter, topping the Zacks’ consensus estimate of $1.79 by $0.04. Pennsylvania-based Addison Capital has invested 5.09% in Johnson & Johnson (NYSE:JNJ). The stock decreased 0.09% or $0.09 on September 22, reaching $102.4. 3M Co (NYSE:MMM) has risen 18.59% since September 24, 2016 and is uptrending. It has outperformed by 72.29% the S&P500.
Among 17 analysts covering Albemarle Corporation (NYSE:ALB), 11 have Buy rating, 0 Sell and 6 Hold. Therefore 100% are positive. Johnson & Johnson had 65 analyst reports since August 7, 2015 according to SRatingsIntel. Johnson & Johnson has a consensus rating of Hold and a consensus target price of $135.29. BidaskClub raised Johnson & Johnson from a “buy” rating to a “strong-buy” rating in a research report on Saturday, June 17th. The rating was initiated by Standpoint Research with “Sell” on Friday, May 20. JP Morgan upgraded Johnson & Johnson (NYSE:JNJ) on Monday, May 15 to “Overweight” rating. Jefferies has “Buy” rating and $120 target. The firm has “Buy” rating given on Thursday, August 31 by BMO Capital Markets. The rating was maintained by RBC Capital Markets on Wednesday, October 7 with “Outperform”. UBS AG reissued a “buy” rating and set a $148.00 price target (up previously from $136.00) on shares of Johnson & Johnson in a research report on Wednesday, July 19th. The rating was upgraded by Argus Research to “Buy” on Wednesday, July 20.
Johnson & Johnson earned a daily sentiment score of 0.09 on Accern’s scale. Its down 0.03, from 0.86 in 2017Q1. It is negative, as 50 investors sold JNJ shares while 878 reduced holdings. 105 funds opened positions while 667 raised stakes. Ltd. boosted its holdings in shares of Johnson & Johnson by 29.9% in the second quarter. Corporate insiders own 0.19% of the company’s stock. Toth Advisory Corp accumulated 1.88% or 54,289 shares. Liberty Cap Management Inc has 0.58% invested in Johnson & Johnson (NYSE:JNJ) for 7,339 shares. Wallace Cap Mngmt Inc reported 2.25% of its portfolio in Johnson & Johnson (NYSE:JNJ). Ing Groep Nv has 24,207 shares for 0.01% of their portfolio. Homrich Berg stated it has 40,041 shares. Bank of Nova Scotia now owns 1,171,517 shares of the company’s stock worth $145,914,000 after purchasing an additional 569,313 shares during the period. Mgmt Associate Ny reported 2,500 shares. Sumitomo Life Insurance Company reported 1.81% of its portfolio in Johnson & Johnson (NYSE:JNJ).
Johnson & Johnson had 66 analyst reports since August 7, 2015 according to SRatingsIntel. They expect $1.79 earnings per share, up 6.55% or $0.11 from last year’s $1.68 per share. JNJ’s profit will be $4.79B for 18.35 P/E if the $1.79 EPS becomes a reality. It now has negative earnings. It also increased its holding in Pfizer Inc (NYSE:PFE) by 80,574 shares in the quarter, for a total of 985,559 shares, and has risen its stake in B2gold Corp (NYSEMKT:BTG). Stearns Financial Serv holds 1.72% in Johnson & Johnson (NYSE:JNJ) or 54,027 shares. More interesting news about Johnson & Johnson (NYSE:JNJ) were released by: Seekingalpha.com and their article: “Johnson & Johnson Acquires Sightbox For Contact Lens Subscriptions” published on September 22, 2017 as well as Usatoday.com’s news article titled: “Pfizer accuses Johnson & Johnson of “anticompetitive practices” in lawsuit” with publication date: September 20, 2017.
Since June 19, 2017, it had 0 insider buys, and 2 insider sales for $3.24 million activity. Vicus Capital lifted its holdings in shares of Johnson & Johnson by 2.6% in the 2nd quarter. About 2.79 million shares traded or 34.78% up from the average. 3,016 shares were sold by Price Kimberly F, worth $597,500. Clearbridge Investments LLC now owns 9,543,827 shares of the company’s stock valued at $1,188,684,000 after purchasing an additional 310,831 shares in the last quarter. Clearbridge Investments LLC increased its stake in Johnson & Johnson by 3.4% in the 1st quarter.
Investors sentiment increased to 0.91 in 2017 Q2. Its up 0.02, from 1.23 in 2017Q1. It improved, as 45 investors sold MMM shares while 589 reduced holdings. 387.02 million shares or 0.60% more from 384.71 million shares in 2017Q1 were reported. Payden Rygel reported 163,700 shares stake. After $3.86 actual earnings per share reported by NetEase Inc (ADR) for the previous quarter, Wall Street now forecasts -31.09% negative EPS growth. Lee Danner Bass Incorporated holds 109,691 shares or 1.63% of its portfolio. Copper Rock Partners Ltd holds 0.01% or 1,944 shares. Advantus Capital reported 271,864 shares or 0.95% of all its holdings. Wallington Asset Limited Liability Com has 3.79% invested in 3M Co (NYSE:MMM). Karpas Strategies Limited Com owns 138,970 shares for 8.29% of their portfolio. North Amer Mngmt has invested 2.36% in 3M Co (NYSE:MMM).
Shares of Johnson & Johnson (NYSE:JNJ) opened at 131.39 on Wednesday. The company’s quarterly revenue was up 1.9% compared to the same quarter a year ago.